https://www.fiercebiotech.com/biotech/protalix-chiesi-edge-close-to-potential-fabry-disease-approval
0
0
5/28/20 at 11:50am
Organization
FierceBiotech
Author
Ben Adams
Israeli biotech Protalix BioTherapeutics and partner Chiesi have sent off their Biologics License Application for rare disease hopeful pegunigalsidase alfa to the FDA.
Create an account
or login to join the discussion